Apr 19 2024 This Week in Cardiology
Episode description
ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
I. TACT 2
Chelation Therapy Provides No Benefit Post-MI
https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5
Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src=
- JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238
- Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/
- A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003
- PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
II. Interatrial Shunts for HF
No Net HF Benefit for Interarterial Shunt Device
https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk
- REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2
III. Triglyceride Lowering
Early Olezarsen Results Show 50% Reduction in Triglycerides
Is It Time to Stop Treating High Triglycerides?
https://www.medscape.com/viewarticle/990126
Substantial Triglyceride Reduction With Plozasiran
IV. Diltiazem and Factor Xa inhibitors
- JAMA Vanderbilt University Paper https://jamanetwork.com/journals/jama/fullarticle/2817546
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net